RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA(TM)) for H. pylori Infection
Subject to a successful outcome and any additional regulatory feedback, the
confirmatory Phase III study
(ERADICATE Hp 2) is expected to complete the package required for a potential U.S. NDA for RHB-105, newly branded as TALICIA
The two-arm, randomized, double-blind, active comparator, confirmatory Phase III study is planned to enroll 444 non-investigated dyspepsia patients with confirmed H. pylori infection in up to 65 clinical sites in the U.S., with a primary endpoint of eradication of H. pyloriinfection at 42 through 70 days after initiation of treatment
The first Phase III study with
RHB-105) (ERADICATE Hp) successfully demonstrated 89.4% efficacy in eradicating H. pylori infection (p<0.001), supporting the potential superior efficacy of TALICIA
RHB-105) over current standard-of-care (SoC) therapies
RHB-105) was granted QIDP designation by the FDA under the GAIN Act, including Fast-Track development, NDA Priority Review and extended U.S. market exclusivity, for a total of eight years
bacterial infection is a major cause of chronic gastritis, peptic ulcer disease, gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma and is estimated to affect over half of the adult population worldwide
The World Health Organization (WHO) recently published a global priority list of 12 life-threatening multidrug-resistant bacteria, in which H. pylori infection was classified in group 2 high-priority bacteria for which new treatments are urgently needed
- The 2015 global and U.S. market potential for H. pylori eradication therapies at current branded prices, were estimated at approximately $4.83 billion and $1.45 billion, respectively
TEL-AVIV, Israel and RALEIGH, N.C., June 15, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced the initiation of a confirmatory Phase III study with RHB-105, newly branded as TALICIA(TM)1, for the treatment of H. pylori infection (the ERADICATE Hp 2 study).
TALICIA(TM) (RHB-105) is a proprietary, fixed-dose, oral combination therapy of two antibiotics and a proton pump inhibitor (PPI) in an all-in-one oral capsule for the eradication of H. pylori infection.
The two-arm, randomized, double-blind, active comparator confirmatory Phase III ERADICATE Hp 2 study will compare TALICIA(TM) (RHB-105) against a dual therapy amoxicillin and omeprazole regimen at equivalent doses. The study is planned to enroll 444 non-investigated dyspepsia patients with confirmed H. pylori infection in up to 65 clinical sites in the U.S. Subjects will be randomized in a 1:1 ratio to receive four capsules, three times daily, of either TALICIA(TM) (RHB-105) or the active comparator, for a period of 14 days. Subjects will be assessed for the study's primary endpoint of eradication of H. pyloriinfection at 42 through 70 days after initiation of treatment.
Subject to its successful outcome and any additional regulatory feedback, the confirmatory Phase III study, along with the results from the successfully completed first Phase III study with TALICIA(TM) (RHB-105) (the ERADICATE Hp study) and data from the completed supportive PK program, are expected to support a potential U.S. New Drug Application (NDA) for TALICIA(TM) (RHB-105).
The first Phase III study with TALICIA(TM) (RHB-105) successfully met its protocol-defined mITT primary endpoint of superiority over historical standard-of-care (SoC) eradication rate of 70%, with high statistical significance (p<0.001). The study results demonstrated 89.4% efficacy in eradicating H. pylori infection with TALICIA(TM) (RHB-105). Notably, the 89.4% efficacy in eradicating H. pylori infection with TALICIA(TM)(RHB-105) was also superior to subsequent open-label treatment with SoC therapies of patients in the placebo arm of the ERADICATE Hp study, which demonstrated 63% eradication rate in the mITT population (p=0.006), further supporting the potential efficacy of TALICIA(TM) (RHB-105) as a treatment forH. pylori infection. Treatment with TALICIA(TM) (RHB-105) appeared to be safe and well tolerated.
TALICIA(TM) (RHB-105) was granted Qualifying Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration (FDA), providing a Fast-Track development pathway, as well as NDA Priority Review status, potentially leading to a shorter NDA review time by the FDA, if filed. If approved, TALICIA(TM) (RHB-105) is entitled to receive, thanks to its QIDP status, an additional five years of U.S. market exclusivity, in addition to the standard exclusivity period, for a total of 8 years of U.S. market exclusivity.
RedHill is pursuing with TALICIA(TM) (RHB-105) an indication of first-line treatment of H. pylori infection, regardless of ulcer status, a significantly broader indication than current standard treatments for H. pylori, which are typically indicated only for patients with active or recent history of duodenal ulcer disease. If approved, TALICIA(TM) (RHB-105) may be the first H. pylori eradication therapy in the U.S. to target this broader indication, which would significantly expand the potential patient population for this drug candidate.
H. pylori bacterial infection is a major cause of chronic gastritis, peptic ulcer disease, gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. H. pylori infection is estimated to affect over half of the adult population worldwide2. The growing resistance of the H. pylori bacteria to metronidazole and clarithromycin has resulted in increasing failure rates of current SoC for H. pylori eradication, reaching an estimated 30%3. Despite the strong unmet medical need, no new drug has been approved by the FDA for this indication in over a decade. The World Health Organization (WHO) recently published a global priority list of 12 life-threatening multidrug-resistant bacteria, in which H. pylori infection was classified as a high-priority bacteria for which new treatments are urgently needed4.
The 2015 global and U.S. market potential for H. pylori eradication therapies at branded prices, were estimated at approximately $4.83 billion and $1.45 billion, respectively, and could potentially grow with increasing awareness of the health risks associated with H. pylori infection and the benefits of its eradication5.
The confirmatory Phase III ERADICATE Hp 2 study with TALICIA(TM) (RHB-105) will be registered on www.ClinicalTrials.gov, a web-based service of the U.S. National Institutes of Health, which provides access to information on publicly and privately supported clinical studies.
About TALICIA(TM) (RHB-105):
RHB-105, newly branded as TALICIA(TM), is a new and proprietary fixed-dose oral combination therapy of two antibiotics and a proton pump inhibitor (PPI) in an all-in-one oral capsule with a planned indication for the treatment of H. pylori infection. H. pylori bacterial infection is a major cause of chronic gastritis, peptic ulcer disease, gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. A first Phase III study with TALICIA(TM) (RHB-105) (the ERADICATE Hp study) was completed in the U.S. with positive results. The study demonstrated an overall success rate of 89.4% in eradicating H. pylori, and met its protocol-defined primary endpoint of superiority in eradication of H. pylori infection over historical standard-of-care efficacy levels of 70%, with high statistical significance (p<0.001). A confirmatory Phase III study (ERADICATE Hp 2 study) has been initiated in the U.S. Additional studies may be required, subject to FDA review. TALICIA(TM) (RHB-105) has been granted Qualifying Infectious Disease Product (QIDP) designation by the FDA, providing a Fast-Track development pathway, as well as NDA Priority Review status, potentially leading to a shorter NDA review time by the FDA, if filed. If approved, TALICIA(TM) (RHB-105) will also receive an additional five years of exclusivity, in addition to the standard exclusivity period, for a total of 8 years of U.S. market exclusivity.
About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) is a specialty biopharmaceutical company headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. RedHill promotes two gastrointestinal products in the U.S. - Donnatal® , a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis, and EnteraGam® , a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. RedHill's clinical-stage pipeline includes: (i) TALICIA(TM) (RHB -105) - an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; (ii) RHB-104 -an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis and QIDP status for nontuberculous mycobacteria (NTM) infections; (iii) BEKINDA® (RHB-102) - a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; (iv) RHB-106 - an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) YELIVA® (ABC294640) - a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory and gastrointestinal indications; (vi) MESUPRON - a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors and (vii) RIZAPORT® (RHB-103) - an oral thin film formulation of rizatriptan for acute migraines, with a U.S. NDA currently under discussion with the FDA and marketing authorization received in two EU member states under the European Decentralized Procedure (DCP). More information about the Company is available at: www.redhillbio.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates; (v) the Company's ability to successfully market Donnatal® and EnteraGam®, (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and of the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; and (xii) estimates of the Company's expenses, future revenues capital requirements and the Company's needs for additional financing; (xiii) competitive companies and technologies within the Company's industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on February 23, 2017. All forward-looking statements included in this Press Release are made only as of the date of this Press Release. We assume no obligation to update any written or oral forward-looking statement unless required by law.
1 TALICIA(TM) is an investigational new drug, not available for commercial distribution.
2 Hunt, R. H., et al. "Helicobacter pylori in developing countries." World Gastroenterology Organisation Global Guidelines (2010): 1-15.
3 Malfertheiner P. et al. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report, Gut 2012;61:646-664.
4 WHO report - Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics: http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/
5 Jerry Rosenblatt, Ph.D., a member of RedHill's Advisory Board and Partner at Foster Rosenblatt, RedHill Biopharma press release: RedHill Biopharma's Investor Webcast Forum Provides Update on the RHB-105 Phase III Program and Potential H. Pylori Eradication Market, May 18, 2015.
Company contact: Adi Frish Senior VP Business Development & Licensing RedHill Biopharma +972-54-6543-112 email@example.com IR contact (U.S.): Marcy Nanus Senior Vice President The Trout Group +1-646-378-2927 Mnanus@troutgroup.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: RedHill Biopharma Ltd. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Orion Biotechnology Canada Announces Closing of $5 Million Financing20.3.2018 22:03 | Pressemelding
OTTAWA, March 20, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd today announced it has completed a US$5 million private placement financing late last year. "We are delighted to have secured the financial resources during this period of rapid expansion," said Mark Groper, President and Chief Executive Officer. "This financing allows Orion, as a private company, to continue development of its expanding pipeline of innovative products, including expansion of our infrastructure and human resources. It also provides external validation of the unique value proposition of the company's pipeline products which include candidates in the areas of Sexual Health, Oncology and Multiple Sclerosis. Orion is a research and development organization committed to developing novel approaches to address serious health issues. A prime example of this is the company's microbicide candidate, OB-001, which is being evaluated as a contraceptive gel which also prevents the transmission of HIV. "This is
Meltwater acquires privacy-by-design social data platform DataSift to strengthen its AI-driven analytics offering20.3.2018 18:45 | Pressemelding
SAN FRANCISCO, March 20, 2018 (GLOBE NEWSWIRE) -- Meltwater, a pioneer of media intelligence and now Outside Insight, today announced its acquisition of DataSift, a privacy-by-design data and analytics platform that extracts real-time insights from social and online data sources, while protecting user privacy. This acquisition, Meltwater's sixth in the last year, solidifies the company's emergence as a leading provider of AI-powered competitive intelligence through its Outside Insight platform. "By combining advances in machine learning and the vast amount of publicly available information on the internet, you can today understand and track Porter's Five Forces in real time to understand strategic opportunities and threats for your business. Executives that take advantage of this new opportunity create an unfair information advantage over those who don't," explained Jorn Lyseggen, CEO and founder of Meltwater. "DataSift has built a scalable platform that lets developers build data scie
VITEC Adds Powerful New Video Wall and DRM Functionality to EZ TV IPTV and Digital Signage Platform20.3.2018 17:00 | Pressemelding
SUNNYVALE, Calif., March 20, 2018 (GLOBE NEWSWIRE) -- VITEC, a worldwide leader in advanced video encoding and streaming solutions, today announced that its award-winning, enterprise-grade EZ TV IPTV and Digital Signage Platform can now manage and drive complex video wall setups and is interoperable with the latest content protection and DRM standards required by the leading services providers for IPTV deployments. These capabilities are fully supported through the EZ TV Platform, with DRM integration also available across VITEC's IPTV set-top-boxes, signage end-points, and the cutting-edge EZ TV IPTV mobile app. Attendees will see a live demonstration of the new EZ TV release at the 2018 NAB Show, April 9-12, at the Las Vegas Convention Center - booth SL6821. VITEC's video wall solution is designed to simplify deployment and management of projects involving IPTV, digital signage, and video wall content, while delivering a breathtaking visual experience. The new EZ TV video wall proces
Librestream Powers New Remote Assistance Service from Safran Helicopter Engines20.3.2018 16:00 | Pressemelding
WINNIPEG, Manitoba, March 20, 2018 (GLOBE NEWSWIRE) -- Librestream is pleased to announce that Safran Helicopter Engines has successfully deployed a remote video technical assistance service using the Onsight collaborative platform. Safran Helicopter Engines first announced this innovative Expert link branded service at the HAI Heli-Expo February 28 in conjunction with Heli Austria, Rotortech Services Inc and Heligo, first customers of this new service. Using the Expert link service, helicopter operators can connect immediately with remote experts at Safran Helicopter Engines to assist with technical diagnostics and maintenance tasks. The service includes a secure live video feed that remotely brings the eyes and ears of Safran experts into customer facilities to mentor and share maintenance best practices. "We felt that Expert link was an important part of our digital service strategy, which also includes services such as our EngineLife® Customer Portal and Health Monitoring solutions
SD-WAN Market Report Names Aryaka Top Independent Pure Play SD-WAN Market Leader Again in CY Q4 201720.3.2018 14:53 | Pressemelding
IHS Markit Report illustrates SD-WAN market is a two-horse race between Aryaka and VMware, showcases Aryaka's significant lead over Cisco, Riverbed, Silver-Peak, and others SAN MATEO, Calif., March 20, 2018 (GLOBE NEWSWIRE) -- Aryaka® maintained its position as the largest independent pure play SD-WAN provider by market share and revenues, and continued its march to close the gap on VMware in Q4 2017, according to the latest industry report from IHS Markit. The "IHS Markit's Data Center Network Equipment Quarterly Market Tracker" says Aryaka garnered 17% share of the SD-WAN market in Q4 2017, once again securing the company's lead over legacy networking vendors like Cisco and Riverbed. Aryaka's market share is listed as only 2% less than VMware's. "[Aryaka's] Customer deployments continue to focus on the replacement of MPLS with several large wins in the US, a large service provider partner in Asia Pacific, and a large service provider partner in EMEA serving the automotive sector," Cl
NRT Acquires OfferCraft, Award-Winning Provider of Artificial Intelligence, Gamification and Digital Content Solutions20.3.2018 14:22 | Pressemelding
Acquisition of hyper-engagement platform enhances NRT's ability to deliver transformative, revenue-generating technology to its customers LAS VEGAS, March 20, 2018 (GLOBE NEWSWIRE) -- NRT Technology Corp. ("NRT"), a leading provider of digital commerce experiences in gaming and financial services, announced that it has acquired the assets of privately held OfferCraft, a software company that uses artificial intelligence and gamification to drive loyalty, engagement and revenue. Terms of the agreement are not disclosed. The deal will allow NRT to integrate OfferCraft's patent-pending solutions into its existing kiosk, mobile, table games and cashless payment product lines, while also expanding into entirely new areas across nearly every digital channel. OfferCraft's artificial intelligence software allows offers, coupons and rewards to be distributed digitally across email, SMS, websites, social media, kiosks, the Point of Sale, signage, and more. Unlike traditional marketing content, t
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom